{"id":"W4247542270","doi":"10.1016/j.annonc.2020.08.978","title":"839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; Eisai; Astellas Pharma; Amgen; Deciphera Pharmaceuticals; Agios Pharmaceuticals; Foundation Medicine; Sierra Oncology; Pfizer; Innovent Biologics; Symphogen; Incyte; Taiho Pharmaceutical; Jazz Pharmaceuticals; Ipsen; Five Prime Therapeutics; Plexxikon; Clovis Oncology; IFM Therapeutics; Valeant Pharmaceuticals International; Vertex Pharmaceuticals; Carrick Therapeutics; Bristol-Myers Squibb; AstraZeneca; Astex Pharmaceuticals","keywords":"Medicine; Internal medicine; Regimen; Paclitaxel; Carboplatin; Ovarian cancer; Oncology; Chemotherapy; Cancer; Metastatic breast cancer; Gastroenterology; Breast cancer; Urology; Surgery; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096286,0.0009542329,0.002029446,0.0005177097,0.0004124748,0.001061842,0.0007775326,0.001262104,0.007218715],"category_scores_gemma":[0.0005568176,0.0005202442,0.0009830652,0.0005177694,0.0007062083,0.0006188414,0.0003121218,0.003280279,0.001705852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008962021,"about_ca_system_score_gemma":0.001609063,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002745562,"about_ca_topic_score_gemma":0.005863415,"domain_scores_codex":[0.9997289,0.0001093868,0.00001148036,0.00004064296,0.0000260721,0.00008351898],"domain_scores_gemma":[0.9997029,0.00004684922,0.000033247,0.00003009861,0.00001923187,0.0001676705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6047598,0.05278503,0.00572569,0.00113436,0.001943492,0.0007283064,0.0002691406,0.004679757,0.0876982,0.0008904351,0.01539298,0.2239927],"study_design_scores_gemma":[0.6629207,0.3001279,0.0141982,0.00006671622,0.000784596,0.0006843458,0.0001147188,0.002288507,0.007618971,0.0004466713,0.01070005,0.00004861495],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846874,0.002817632,0.0006822606,0.001154192,0.0002476049,0.002086238,0.002137703,0.0002784003,0.005908678],"genre_scores_gemma":[0.9773319,0.003810424,0.001784456,0.001273381,0.0001879601,0.001921986,0.004677793,0.0001159455,0.008896077],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007218715,"threshold_uncertainty_score":0.024149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1226322187301675,"score_gpt":0.4307895065156807,"score_spread":0.3081572877855131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}